Literature DB >> 23830361

Prognostic impact of lymphovascular invasion compared with that of visceral pleural invasion in patients with pN0 non-small-cell lung cancer and a tumor diameter of 2 cm or smaller.

Hiroyuki Tao1, Tatsuro Hayashi, Fumiho Sano, Akihiro Takahagi, Toshiki Tanaka, Eisuke Matsuda, Kazunori Okabe.   

Abstract

BACKGROUND: Both visceral pleural invasion (VPI) and lymphovascular invasion (LVI) have been shown to be adverse prognostic factors for early-stage non-small-cell lung cancer (NSCLC). Positive VPI upstages the T category of tumors ≤ 2 cm (T1a) to T2a, whereas LVI is not adapted as a descriptor for the Tumor, Node, Metastasis classification system. This study was conducted to evaluate the prognostic impacts of VPI and LVI in patients with pN0 NSCLC and a tumor diameter of ≤ 2 cm.
METHODS: We reviewed records of a total of 142 patients with pN0 NSCLC and a tumor diameter of ≤ 2 cm, who underwent lobectomy with hilar and mediastinal lymph node dissection between January 2001 and December 2009. We conducted univariate and multivariate analyses to evaluate the impact of VPI, LVI, and other clinicopathologic factors on survival.
RESULTS: Visceral pleural invasion and LVI were diagnosed as positive in 18 (12.7%) and 22 (15.5%) patients, respectively. Male sex, squamous cell carcinoma, positive VPI, and positive LVI were risk factors for overall survival. Squamous cell carcinoma, positive VPI, and positive LVI were risk factors for relapse-free survival. In multivariate analysis, squamous cell carcinoma and positive LVI were independent risk factors for overall survival, and positive LVI was an independent risk factor for relapse-free survival.
CONCLUSIONS: Positive LVI was more important than VPI as a prognostic factor in patients with pN0 NSCLC and a tumor diameter of ≤ 2 cm. Adjuvant chemotherapy should be considered for such patients, to improve the treatment outcomes.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Lymphovascular invasion; Non–small-cell lung cancer; Prognostic factor; Recurrence; Visceral pleural invasion

Mesh:

Year:  2013        PMID: 23830361     DOI: 10.1016/j.jss.2013.05.104

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  11 in total

1.  Prognosis After Sublobar Resection of Small-sized Non-small Cell Lung Cancer with Visceral Pleural or Lymphovascular Invasion.

Authors:  Youngkyu Moon; Kyo Young Lee; Jae Kil Park
Journal:  World J Surg       Date:  2017-11       Impact factor: 3.352

2.  Clinicopathological features of small-sized peripheral squamous cell lung cancer.

Authors:  Takayuki Kosaka; Kimihiro Shimizu; Seshiru Nakazawa; Misaki Iijima; Yoichi Ohtaki; Yoko Azuma; Kai Obayashi; Toshiteru Nagashima; Toshiki Yajima; Akira Mogi; Hiroyuki Kuwano; Ken Shirabe
Journal:  Mol Clin Oncol       Date:  2019-11-18

3.  Risk analysis in peripheral clinical T1 non-small cell lung cancer correlations between tumor-to-blood standardized uptake ratio on 18F-FDG PET-CT and primary tumor pathological invasiveness: a real-world observational study.

Authors:  Xiao-Feng Li; Yun-Mei Shi; Rong Niu; Xiao-Nan Shao; Jian-Feng Wang; Xiao-Liang Shao; Fei-Fei Zhang; Yue-Tao Wang
Journal:  Quant Imaging Med Surg       Date:  2022-01

4.  Impact of microvascular invasion on 5-year overall survival of resected non-small cell lung cancer.

Authors:  Andreia Salarini Monteiro; Sérgio Ricardo de Carvalho Araújo; Luiz Henrique Araujo; Mirian Carvalho de Souza
Journal:  J Bras Pneumol       Date:  2022-07-08       Impact factor: 2.800

5.  Difference in Postsurgical Prognostic Factors between Lung Adenocarcinoma and Squamous Cell Carcinoma.

Authors:  Haruhiko Nakamura; Hiroki Sakai; Hiroyuki Kimura; Tomoyuki Miyazawa; Hideki Marushima; Hisashi Saji
Journal:  Ann Thorac Cardiovasc Surg       Date:  2017-10-02       Impact factor: 1.520

Review 6.  Optimal delivery of follow-up care following pulmonary lobectomy for lung cancer.

Authors:  Ying-Yi Chen; Tsai-Wang Huang; Hung Chang; Shih-Chun Lee
Journal:  Lung Cancer (Auckl)       Date:  2016-03-30

7.  [High risk indication of postoperative chemotherapy 
in early stage non-small cell lung cancer].

Authors:  Feng Mao; Yan Pan; Ziming Li; Minghui Cai; Yang Shen-Tu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2014-05

8.  Risk factors of recurrence for resected T1aN0M0 invasive lung adenocarcinoma: a clinicopathologic study of 177 patients.

Authors:  Fan Yang; Kezhong Chen; Yida Liao; Xiao Li; Kunkun Sun; Dongmei Bao; Jun Wang
Journal:  World J Surg Oncol       Date:  2014-09-13       Impact factor: 2.754

9.  The clinical prognostic factors of patients with stage IB lung adenocarcinoma.

Authors:  Qihai Sui; Jiaqi Liang; Zhengyang Hu; Xinming Xu; Zhencong Chen; Yiwei Huang; Mengnan Zhao; Cheng Zhan; Lin Wang; Zongwu Lin; Qun Wang
Journal:  Transl Cancer Res       Date:  2021-11       Impact factor: 1.241

10.  Survival Prediction Model Using Clinico-Pathologic Characteristics for Nonsmall Cell Lung Cancer Patients After Curative Resection.

Authors:  Ching-Yang Wu; Jui-Ying Fu; Ching-Feng Wu; Ming-Ju Hsieh; Yun-Hen Liu; Yi-Cheng Wu; Cheng-Ta Yang; Ying-Huang Tsai
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.